<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Abstract: Current classification criteria for definite APS recommend the use of one or more of three positive standardized laboratory assays, including anticardiolipin antibodies (aCL), <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA), and antibodies directed to β(2)<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (anti-β(2)GPI) to detect <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) in the presence of at least one of the two major clinical manifestations (i.e., <z:mp ids='MP_0005048'>thrombosis</z:mp> or pregnancy morbidity) of the syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Several other autoantibodies shown to be directed to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and/or their complexes with <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and/or to proteins of the coagulation cascade, as well as a mechanistic test for resistance to annexin A5 <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity, have been proposed to be relevant to APS </plain></SENT>
<SENT sid="2" pm="."><plain>A task force of worldwide scientists in the field discussed and analyzed critical questions related to 'non-criteria' aPL tests in an evidence-based manner during the 13th International Congress on <z:hpo ids='HP_0003613'>Antiphospholipid Antibodies</z:hpo> (APLA 2010, 13-16 April 2010, Galveston, Texas, USA) </plain></SENT>
<SENT sid="3" pm="."><plain>This report summarizes the findings, conclusions, and recommendations of this task force </plain></SENT>
</text></document>